EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial

Luca Livraghi, Francesca Martella, Matteo Ghilli, Catia Angiolini, Simonetta Magnanini, Erica Moretti, Carmelo Bengala, Emanuela Risi, Elena Molinara, Ilaria Pazzagli, Luca Malorni, Sara Donati und 10 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.115108 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Luca Livraghi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Neoplasm Recurrence, Local, Receptors, Estrogen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Exact Sciences Corporation, Exact Sciences Corp, Sandro Pitigliani Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Data published in 2015 showed that patients with early breast cancer (EBC) and a low-risk (LR) Recurrence Score® (RS) result by the 21-gene Oncotype DX® assay ("the test") did not derive benefit from adding chemotherapy (CT) to endocrine therapy (HT), while those with a high-risk (HR) RS result did. However, the role of CT remained uncertain in patients with intermediate-risk (IR) cancers. We designed a study to assess the test's ability to categorize patients with EBC with uncertain biological behavior into the groups (LR and HR) for which the value of additional chemotherapy was defined. METHODS: The POST trial was a multicenter, prospective cohort study conducted in 14 Breast Centers of the Tuscany region of Italy. Consecutive patients with pT1-2 pN0-N1mi hormone receptor-positive/HER2-negative EBC and uncertain biological behavior based on standard parameters were enrolled. Patients were categorized based on RS results into LR, IR, and HR groups if RS result was 25, respectively. Treatment recommendations by multidisciplinary meeting assessed before and after RS results were available. RESULTS: Of 246 tested samples, 78 were classified as LR or HR, with most of the patients (65.4 %) being at IR. Following test results, the recommendation changed in 15.9 % of cases. Among patients initially recommended for CT or for discussion about the role of CT, respectively 64.3 % and 75.9 % ultimately received recommendation for HT alone. CONCLUSIONS: Our study suggests that RS results can refine treatment decisions for patients with EBC exhibiting uncertain biological behavior initially recommended or considered for CT. (250/250).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesNeoplasm Recurrence, LocalReceptors, EstrogenHumansFemaleProspective StudiesMiddle AgedAgedAdultRisk AssessmentBiomarkers, TumorItalyGene Expression ProfilingRisk FactorsAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, Adjuvant

Stichwörter der Autor:innen

AdjuvantBreast neoplasms / drug therapyBreast neoplasms / pathologyChemotherapyClinical decision-makingGene expression profiling

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, EstrogenBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy.
  • Oncology Unit, Santa Maria Annunziata Hospital, Bagno a Ripoli, Florence, Italy.
  • Breast Centre, University Hospital of Pisa (AOUP), Pisa, Italy.
  • Breast Medical Oncology, Oncology Department, AOU Careggi, Florence, Italy.
  • Breast Oncology Unit, Hospital of Arezzo, Azienda USL Toscana Sud Est, Arezzo, Italy.
  • Medical Oncology Unit, Misericordia Hospital, Grosseto, Italy.

Förderung

  • Exact Sciences Corporation
  • Exact Sciences Corp
  • Sandro Pitigliani Foundation

Zitieren

APA

Livraghi, L., Martella, F., Ghilli, M., Angiolini, C., Magnanini, S., Moretti, E., Bengala, C., Risi, E., Molinara, E., Pazzagli, I., Malorni, L., Donati, S., Gabellini, S., Martignetti, A., Giannessi, P., Sanna, G., Barellini, L., Biagioni, C., Boni, L., …, & Biganzoli, L. (2024). Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.115108

Vancouver

Livraghi L, Martella F, Ghilli M, Angiolini C, Magnanini S, Moretti E, et al. Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.115108

BibTeX
@article{Livraghi2024,
  author = {Livraghi, Luca and Martella, Francesca and Ghilli, Matteo and Angiolini, Catia and Magnanini, Simonetta and Moretti, Erica and Bengala, Carmelo and Risi, Emanuela and Molinara, Elena and Pazzagli, Ilaria and Malorni, Luca and Donati, Sara and Gabellini, Stefano and Martignetti, Angelo and Giannessi, Piergiorgio and Sanna, Giuseppina and Barellini, Leonardo and Biagioni, Chiara and Boni, Luca and Bianchi, Simonetta and Roncella, Manuela and Biganzoli, Laura},
  title = {Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.115108}
}
Kostenlos starten →